Global Kidney Cancer Drugs Market 2015-2019

腎臓がん治療薬の世界市場2015-2019

◆タイトル:Global Kidney Cancer Drugs Market 2015-2019
◆商品コード:IRTNTR6298
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年7月1日
◆ページ数:105
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、腎臓がん治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、腎臓がん治療薬の世界市場規模及び予測、製品パイプライン分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Kidney Cancer
Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms’ tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders.

Kidney cancer can be triggered by a number of factors including both lifestyle-related changes and genetic changes. The surgical removal of affected cancerous cells from the kidney provides a complete cure of the disease. A number of drugs are also available, which also help in the treatment of the disease when it is diagnosed at earlier stages.
Technavio’s analysts forecast the global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.

[Covered in this Report]
The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer.

The three regions covered in the report are as follows:
• Americas: US, Canada, Mexico, and Brazil
• EMEA: UK, Germany, Italy, France, and Spain and Middle Eastern and African countries such Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
• APAC: Japan, China, Australia, Singapore, South Korea, and India.

Technavio’s report, Global Kidney Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Bayer
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novartis
• Pfizer

[Other Prominent Vendors]
• Abbott Laboratories
• Active Biotech
• Amgen
• Argos Therapeutics
• ArQule
• AVEO Pharmaceuticals
• Bionomics
• Bristol-Myers Squibb
• Cerulean Pharma
• Exelixis
• Genentech
• immatics biotechnologies
• Immunicum
• Ono Pharmaceutical
• Onyx Therapeutics
• Oxford BioMedica
• Prometheus Laboratories
• Seattle Genetics
• Taiwan Liposome
• TRACON Pharmaceuticals
• Wilex

[Market Driver]
• Increase in Patient Population
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Drugs
• For a full, detailed list, view our report

[Market Trend]
• Strategic Alliances
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Product Profiles
05.1.1 Nexavar
05.1.2 Avastin
05.1.3 Votrient
05.1.4 Afinitor/Votubia
05.1.5 Proleukin
05.1.6 Inlyta
05.1.7 Sutent
05.1.8 Torisel

06.Introduction

07.Disease Overview
07.1 Understanding the Disease
07.1.1 Types of Kidney Cancer
07.1.2 Benign Kidney Tumors
07.2 Risk Factors
07.2.1 Lifestyle and Job-related Risk Factors
07.2.2 Genetic and Hereditary Risk Factors
07.2.3 Other Risk Factors
07.3 Etiology and Pathogenesis
07.3.1 Inherited Gene Mutations
07.3.2 Acquired Gene Mutations
07.4 Signs and Symptoms
07.5 Diagnosis
07.5.1 Medical History and Physical Exam
07.5.2 Lab Tests
07.5.3 Imaging Tests
07.5.4 Biopsy
07.6 Staging
07.6.1 TNM Staging System
07.7 Management
07.7.1 Surgery
07.7.2 Ablation and Other Local Therapies
07.7.3 Radiation Therapy
07.7.4 Targeted Therapy
07.7.5 Biologic Therapy (Immunotherapy)
07.7.6 Chemotherapy
07.8 Epidemiology
07.9 Economic Burden

08.Pipeline Analysis
08.1 Key Information on Pipeline Candidates
08.1.1 AGS-003
08.1.2 Rencarex
08.1.3 Cometriq
08.1.4 IMA901
08.1.5 AV-951
08.1.6 TroVax
08.1.7 MPDL3280A
08.1.8 Opdivo
08.1.9 Naptumomab Estafenatox
08.1.10 Carfilzomib

09.Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis

10.Market Segmentation by Molecule Type
10.1 Small Molecules
10.2 Biologics

11.Geographical Segmentation

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and Their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and Their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Bayer
19.2.2 F. Hoffmann-La Roche
19.2.3 GlaxoSmithKline
19.2.4 Novartis
19.2.5 Pfizer
19.3 Other and Future Prominent Vendors

20.Global Kidney Cancer Drugs Market: Key Takeaways

21.Key Vendor Analysis
21.1 Bayer
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2014
21.1.4 Business Segmentation by Revenue 2013 and 2014
21.1.5 Geographical Segmentation by Revenue 2014
21.1.6 Business Strategy
21.1.7 Recent Developments
21.1.8 SWOT Analysis
21.2 F. Hoffmann-La Roche
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Business Strategy
21.2.7 Key Information
21.2.8 SWOT Analysis
21.3 GlaxoSmithKline
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2014
21.3.4 Business Segmentation by Revenue 2013 and 2014
21.3.5 Geographical Segmentation by Revenue 2014
21.3.6 Business Strategy
21.3.7 Recent Developments
21.3.8 SWOT Analysis
21.4 Novartis
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 Pfizer
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Business Segmentation by Revenue 2014
21.5.4 Business Segmentation by Revenue 2013 and 2014
21.5.5 Geographical Segmentation by Revenue 2014
21.5.6 Business Strategy
21.5.7 Key Developments
21.5.8 SWOT Analysis

22.Other Reports in This Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Types of Kidney Cancer
Exhibit 3: Types of Benign Kidney Tumor
Exhibit 4: Prevalence of Kidney Cancer by Gender
Exhibit 5: Global Kidney Cancer Drugs Market: Pipeline Portfolio
Exhibit 6: Global Kidney Cancer Drugs Market 2014-2019 ($ billions)
Exhibit 7: Segmentation of Global Kidney Cancer Drugs Market by Molecule Type
Exhibit 8: Segmentation of Global Kidney Cancer Drugs Market by Geography 2014
Exhibit 9: Major Drivers in Global Kidney Cancer Drugs Market
Exhibit 10: Major Challenges in Global Kidney Cancer Drugs Market
Exhibit 11: Major Trends of Global Kidney Cancer Drugs Market
Exhibit 12: Bayer: YoY Growth and Revenue of Nexavar 2010-2014 ($ millions)
Exhibit 13: F. Hoffmann-La Roche: YoY Growth and Revenue of Avastin 2010-2014 ($ millions)
Exhibit 14: GlaxoSmithKline: YoY Growth and Revenue of Votrient 2010-2014 ($ millions)
Exhibit 15: GlaxoSmithKline: Revenue of Votrient by Region 2010-2014 ($ millions)
Exhibit 16: Novartis: YoY Growth and Revenue of Afinitor 2010-2014 ($ millions)
Exhibit 17: Novartis: Revenue of Afinitor by Region 2012-2013 ($ millions)
Exhibit 18: Novartis: YoY Growth and Revenue of Proleukin 2012-2014 ($ millions)
Exhibit 19: Pfizer: YoY Growth and Revenue of Inlyta 2012-2014 ($ millions)
Exhibit 20: Pfizer: YoY Growth and Revenue of Sutent 2010-2014 ($ millions)
Exhibit 21: Global Kidney Cancer Drugs Market: Key Takeaways
Exhibit 22: Bayer: Business Segmentation by Revenue 2014
Exhibit 23: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 24: Bayer: Geographical Segmentation by Revenue 2014
Exhibit 25: Business Segmentation of F. Hoffmann-La Roche 2013
Exhibit 26: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 27: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 28: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 29: GlaxoSmithKline: Business Segmentation by Revenue 2014
Exhibit 30: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 31: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
Exhibit 32: Novartis: Business Segmentation
Exhibit 33: Novartis: Revenue by Business Segmentation 2013
Exhibit 34: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 35: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 36: Pfizer: Business Segmentation by Revenue 2014
Exhibit 37: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 38: Pfizer: Geographical Segmentation by Revenue 2014



【掲載企業】

Bayer, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, TRACON Pharmaceuticals, Wilex

【資料のキーワード】

腎臓がん、腎癌、腎臓がん治療薬、製品パイプライン、製薬、腎臓がん治療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[腎臓がん治療薬の世界市場2015-2019] (Global Kidney Cancer Drugs Market 2015-2019 / IRTNTR6298)販売に関する免責事項
[腎臓がん治療薬の世界市場2015-2019] (Global Kidney Cancer Drugs Market 2015-2019 / IRTNTR6298)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆